Auris Medical secures CHF 47.1 million Series C financing
16 avril 2013
On April 16 Auris Medical announced that it secured CHF 47.1 million Series C financing from Sofinnova Ventures and Sofinnova Partners to advance ground-breaking inner ear therapies through Phase III clinical development.
Sonfinnova Ventures (Menlo Park, CA USA) and Sofinnova Partners (Paris, France), two leading venture capital firms participated in the financing of Auris Medical, a company dedicated to the development of novel therapeutics for the treatment on inner ear disorders.
Froriep Renggli advised Auris Medical on all Swiss law aspects of the financing. The Froriep Renggli team was led by partner Marco A. Rizzi, (M&A, Corporate and Commercial) and included associates Tervel Stoyanov and Cyrill Littmann (both M&A, Corporate and Commercial).